# A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

> **NCT03692910** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 35 (actual)

## Conditions studied

- Bipolar Disorder I
- Bipolar Disorder II
- Major Depressive Episode

## Interventions

- **DRUG:** SAGE-217
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03692910
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2019-05-21
- **Final completion:** 2019-05-21
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03692910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03692910, "A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03692910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*